Indivior has impressed with its first notable news since it spun out of Reckitt Benckiser late last year. The specialty pharma company reported that its schizophrenia drug RBP-7000 met the primary endpoint in a Phase III trial, moving it a step closer to its goal of winning FDA approval in 2017.

…read more

Source: Reckitt Benckiser spinout climbs after PhIII schizophrenia trial hits endpoints


0 No comments